You are here

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

Last updated on December 16, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Desamparados, San Jose, Costa Rica
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension, Hypercholesterolemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
35-79 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Hypertension with three additional risks factors (for example: smoking, type 2
diabetes, family history of early heart disease, history of stroke, age over 55 (men)
and 65 (women)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects currently receiving a statin or stopped statin within 6 months prior to
enrollment.

- Subjects with a history of myocardial infarction and subjects with coronary bypass
graft or intra-coronary interventions.

NCT00407537
Pfizer
Completed
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice
To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Hypertension
  • Hypercholesterolemia
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
Experimental: Caduet
Open label caduet added to usual care regimen followed by investigators.
Intervention: Drug: Amlodipine besylate/atorvastatin calcium single pill combination


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1531
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hypertension with three additional risks factors (for example: smoking, type 2 diabetes, family history of early heart disease, history of stroke, age over 55 (men) and 65 (women)

Exclusion Criteria:

  • Subjects currently receiving a statin or stopped statin within 6 months prior to enrollment.
  • Subjects with a history of myocardial infarction and subjects with coronary bypass graft or intra-coronary interventions.
Sexes Eligible for Study: All
35 Years to 79 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Costa Rica,   Croatia,   Czech Republic,   Dominican Republic,   Indonesia,   Jordan,   Korea, Republic of,   Kuwait,   Lebanon,   Malaysia,   Mexico,   Panama,   Philippines,   Russian Federation,   Saudi Arabia,   Taiwan,   Thailand,   Turkey,   United Arab Emirates,   Venezuela
 
 
NCT00407537
A3841047
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now